Tags

Type your tag names separated by a space and hit enter

glycopyrrolate oral solution

General

Pronunciation:
glye-koe-pye-roe-late


Trade Name(s)

  • Cuvposa

Pregnancy Category
Category C

Ther. Class.
none assigned

Pharm. Class.
anticholinergics

Indications

Prevention of excessive drooling associated with neurologic conditions in patients 3–16 yr.

Action

Competitively inhibits peripheral cholinergic receptors, including salivary glands.

Therapeutic Effect(s):

↓ problem drooling.

Pharmacokinetics

Absorption: Absorption following oral administration is low and variable; absorption is ↓ by a high fat meal.

Distribution: Unknown.

Metabolism and Excretion: Excreted mostly unchanged in urine (65–80%), small amount eliminated as metabolites.

Half-life: 3–3.2 hr.

TIME/ACTION PROFILE

ROUTEONSETPEAK†DURATION
POunknown2.6–3.1 hr6–8 hr
†Blood levels.

Contraindication/Precautions

Contraindicated in:

  • Conditions or concurrent drug therapy for which anticholinergic therapy is contraindicated including glaucoma, paralytic ileus, unstable cardiovascular status due to acute hemorrhage, severe ulcerative colitis, toxic megacolon as a complication of ulcerative colitis, myasthenia gravis
  • Concurrent use of potassium chloride capsules or tablets (passage through GI tract may be delayed).

Use Cautiously in:

  • High ambient temperatures; ↑ risk of heat prostration (fever and heat stroke) due to ↓ sweating)
  • Renal impairment
  • Autonomic neuropathy
  • Ulcerative colitis (↑ doses may ↑ risk of paralytic ileus ["toxic megacolon"] )
  • Hyperthyroidism
  • Coronary heart disease, HF, cardiac tachyarrhythmias, tachycardia, or hypertension
  • Hiatal hernia (may aggravate reflux esophagitis)
  • OB: Use in pregnant women only if clearly needed
  • Lactation: Use cautiously during lactation
  • Pedi: Safety and effectiveness not established in children <3 yr.

Adverse Reactions/Side Effects

CNS: SEIZURES, headache, abnormal behavior, agression, agitation, crying, drowsiness, irritability, moaning, mood altertion, poor impulse control, restlessness

EENT: nasal congestion, blurred vision, nasal dryness, nystagmus

Resp: ↑ viscosity of secretions

CV: tachycardia

GI: INCOMPLETE MECHANICAL INTESTINAL OBSTRUCTION , constipation , dry mouth, vomiting, abdominal discomfort, abdominal distention, abnormal taste, chapped lips, diarrhea, flatulence, intestinal pseudo-obstruction

GU: urinary retention

Derm: flushing, dry skin, pallor, pruritus, rash

F and E: dehydration

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

  • May ↑ levels of digoxin, atenolol, or metformin levels; consider dose reductions or other changes in therapy.
  • Effects may be ↑ by amantadine; consider ↓ dose of glycoypyrrolate.
  • May ↓ levels of haloperidol or levodopa; ↑ glycopyrrolate dose may be required.

Route/Dosage

PO: (Children 3–16 yr): 0.02 mg/kg three times daily initially; titrate in increments of 0.02 mg/kg every 5–7 days (not to exceed 0.1 mg/kg three times daily or 1.5–3 mg per dose ).

Availability

Oral solution (cherry): 1 mg/5 mL

Assessment

  • Assess for constipation (abdominal distension, pain, nausea, vomiting), especially within 4–5 days of initial dose or after dose ↑.

Potential Diagnoses

Implementation

  • PO: Administer at least 1 hr before or 2 hrs after meals.

Patient/Family Teaching

  • Instruct patient or parent to take glycopyrrolate as directed. Use an accurate measuring device (dosing cup) for correct dosing and administer with an oral syringe to ensure dose is taken. Dosing is started low and titrated slowly over several wk; do not ↑ dose without consulting health care professional. Advise patient/parent to read Patient and Caregiver Information prior to starting therapy and with each Rx refill.
  • May cause drowsiness or blurred vision. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • If constipation, diarrhea, signs of urinary retention (inability to urinate, dry diapers or undergarments, irritability, crying), or signs of hypersensitivity (rash, hives, allergic reaction) occur, stop administering glycopyrrolate and notify health care professional.
  • May cause ↓ sweating; avoid overheating. Avoid exposure to hot or very warm environments and notify health care professional immediately if signs of heatstroke (hot, red skin; ↓ alertness or unconsciousness, fast, weak pulse; fast, shallow breathing; ↑ temperature.
  • Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

↓ in chronic, severe drooling.

glycopyrrolate oral solution is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Davis’s Drug Guide App + Web powered by Unbound Medicine provides up-to-date information on 5000+ trade name and generic drugs. View on the web or download App to your iPhone, iPad, or Android smartphone or tablet. Davis Drug Guide PDF. Learn more.

Citation

Quiring, Courtney, et al. "Glycopyrrolate Oral Solution." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. www.drugguide.com/ddo/view/Davis-Drug-Guide/110533/all/glycopyrrolate_oral_solution.
Quiring C, Sanoski CA, Vallerand AH. Glycopyrrolate oral solution. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110533/all/glycopyrrolate_oral_solution. Accessed June 19, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Glycopyrrolate oral solution. In Davis's Drug Guide. Available from https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110533/all/glycopyrrolate_oral_solution
Quiring C, Sanoski CA, Vallerand AH. Glycopyrrolate Oral Solution [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 June 19]. Available from: https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110533/all/glycopyrrolate_oral_solution.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - glycopyrrolate oral solution ID - 110533 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110533/all/glycopyrrolate_oral_solution PB - F.A. Davis Company ET - 16 DB - Davis's Drug Guide DP - Unbound Medicine ER -